āagmanLoginNot investment advice. Data and computed figures, for information only.
Sai Life Sciences Ltd
₹1,394.70
−₹37.40 (−2.61%)
NSE · 15 Oct 2026, close
Market Cap
₹31,606 Cr
CMP
₹1,394.70
52-wk High / Low
₹1,697 / 784
P/E
86.0
P/B
12.7
Book Value
₹117.0
Div Yield
0.00%
ROCE
20.0%
ROE
15.4%
Face Value
₹1
D/E
0.12
Price+61.9% over 1Y
āagman read
Computed by āagmanPiotroski F-Score
8
/ 9
8 of 9 F-score tests passed
Graham Number
₹208
√(22.5 × EPS × book value per share)
ROIC
12.6%
vs 11.2% sector median
Cash flow to profit
1.46
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
+232
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
15.4%
ROE × earnings retention ratio
ROE stability
5.0
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom −0.11FII −1.26DII +0.78
Latest quarter vs the previous one
Cash-accrual divergence
−4.7%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.2x)
+Piotroski F-Score of 8/9 is in the strong band (≥7)
Watch-outs
Peer comparison
| Name | P/E | Mar Cap ₹ Cr | ROCE % | ROE % |
|---|
Quarterly results
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 |
| OPM % | 25.0% | 28.5% | 9.3% | 25.8% | 27.3% | 27.2% | 24.4% | 27.2% | 33.8% | 29.4% | 26.7% |
| Other Income | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 |
| Profit before tax | 53 | 76 | −18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 |
| Net Profit | 40 | 56 | −14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS (₹) | — | — | — | — | 2.59 | 4.24 | 2.90 | 4.00 | 4.75 | 4.92 | 3.45 |
Profit & Loss
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 | 2,250 |
| Expenses | 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,559 | 1,592 |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 634 | 658 |
| OPM % | 25.3% | 23.1% | 22.0% | 14.5% | 13.9% | 19.6% | 24.2% | 28.9% | 29.2% |
| Other Income | 6 | 18 | 27 | 28 | 27 | 29 | 35 | 40 | 35 |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 41 | 35 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 167 | 175 |
| Profit before tax | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 466 | 483 |
| Net Profit | 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 | 362 |
| EPS (₹) | — | — | — | — | — | — | 8.16 | 16.48 | 17.12 |
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 | — |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 | — |
| Borrowings | 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 | — |
| Other Liabilities | 247 | 312 | 318 | 527 | 358 | 359 | 665 | 841 | — |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 | — |
| Fixed Assets | 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 | — |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 | — |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 | — |
| Other Assets | 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,477 | — |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,613 | — |
Cash Flows
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 129 | 116 | −36 | 105 | 219 | 263 | 314 | 509 |
| Cash from Investing Activity | −158 | −262 | −260 | −102 | −99 | −191 | −536 | −395 |
| Cash from Financing Activity | 268 | −4 | 296 | 72 | −201 | −95 | 301 | −124 |
| Net Cash Flow | 239 | −150 | −1 | 75 | −80 | −24 | 79 | −9 |
Ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 13.0 | 9.0 | 3.0 | 6.0 | 11.0 | 14.0 | 20.0 |
| ROE % | — | — | — | — | — | — | — | 15.4 |
| EPS (₹) | — | — | — | — | — | — | 8.16 | 16.48 |
| Book Value (₹) | — | — | — | — | — | — | — | 117.0 |
| Face Value (₹) | — | — | — | — | — | — | — | 1 |
| P/E | — | — | — | — | — | — | — | 86.0 |
| Div Yield % | — | — | — | — | — | — | — | 0.00 |
| NPM % | 10.4 | 10.2 | 7.8 | 0.7 | 0.8 | 5.6 | 9.8 | 15.6 |
| OPM % | 25.0 | 23.0 | 22.0 | 15.0 | 14.0 | 20.0 | 24.0 | 29.0 |
| D/E | 0.35 | 0.38 | 0.74 | 0.86 | 1.05 | 0.95 | 0.17 | 0.12 |
| P/B | — | — | — | — | — | — | — | 12.7 |
Growth
Compounded sales growth
5 years+24.0%
3 years+22.0%
TTM+18.0%
Compounded profit growth
5 years+42.0%
3 years+227.0%
TTM+51.0%
Stock price CAGR
Last year+73.0%
Return on equity
5 years9.0%
3 years13.0%
Last year15.0%
Documents
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Board Meeting Intimation for Unaudited Financial Results Of Q-2 (FY 2026-27)Closure of Trading WindowAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPSShareholder Meeting / Postal Ballot-Scrutinizer''s ReportCorporate actions
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman